



**SERES**  
THERAPEUTICS™

## **Seres Therapeutics to Host Second Quarter 2016 Financial Results and Operational Progress Conference Call and Webcast on August 11, 2016**

August 5, 2016

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 5, 2016-- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading microbiome therapeutics platform company, today announced that management will host a conference call and live audio webcast on Thursday, August 11, 2016 at 8:30 a.m. ET to discuss second quarter 2016 results.

This Smart News Release features multimedia. View the full release here: <http://www.businesswire.com/news/home/20160805005067/en/>

To access the conference call, please dial 844-277-9450 (domestic) or 336-525-7139 (international) and reference the conference ID number 60863839. To join the live webcast please visit the "Investors and Media" section of the Seres website at [www.serestherapeutics.com](http://www.serestherapeutics.com).

A webcast replay will be available on the Seres website beginning approximately two hours after the event and will be archived for 21 days.

### **About Seres Therapeutics**

Seres Therapeutics, Inc. is a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, where the natural state of bacterial diversity and function is imbalanced. Seres' program SER-109 continues to be evaluated in a Phase 2 study in multiply recurrent CDI. Seres' second clinical candidate, SER-287, is being evaluated in a Phase 1b study in patients with mild-to-moderate ulcerative colitis (UC). Seres is also developing SER-262, the first ever synthetic microbiome therapeutic candidate, in a Phase 1b study in patients with primary CDI. For more information, please visit [www.serestherapeutics.com](http://www.serestherapeutics.com). Follow us on Twitter @SeresTx.



View source version on businesswire.com: <http://www.businesswire.com/news/home/20160805005067/en/>

Source: Seres Therapeutics, Inc.

### **IR and PR Contact:**

Seres Therapeutics  
Carlo Tanzi, Ph.D., 617-203-3467  
Head of Investor Relations and Corporate Communications  
[Ctanzi@serestherapeutics.com](mailto:Ctanzi@serestherapeutics.com)